Yanan Ma, Wanshui Yang, Tracey G. Simon, Stephanie A. Smith‐Warner, Teresa T. Fung, Jing Sui, Dawn Chong, Trang VoPham, Jeffrey A. Meyerhardt, Deliang Wen, Edward L. Giovannucci, Andrew T. Chan, Xuehong Zhang – 1 December 2018 – Although adherence to healthy dietary guidelines has been associated with a reduced risk of several health outcomes, including cardiovascular diseases, type 2 diabetes, and some cancers, little is known about the role of dietary patterns in the development of hepatocellular carcinoma (HCC).

Jian‐Hong Fang, Li Xu, Li‐Ru Shang, Chu‐Zhi Pan, Jin Ding, Yun‐Qiang Tang, Hui Liu, Chu‐Xing Liu, Jia‐Lin Zheng, Yao‐Jun Zhang, Zhong‐Guo Zhou, Jing Xu, Limin Zheng, Min‐Shan Chen, Shi‐Mei Zhuang – 1 December 2018 – Sorafenib is the most recommended first‐line systemic therapy for advanced hepatocellular carcinoma (HCC). Yet there is no clinically applied biomarker for predicting sorafenib response.

Eduardo Vilar‐Gomez, Raj Vuppalanchi, Samer Gawrieh, Marwan Ghabril, Romil Saxena, Oscar W. Cummings, Naga Chalasani – 1 December 2018 – Vitamin E improves liver histology in adults with nonalcoholic steatohepatitis (NASH) but not diabetes, but its impact on long‐term patient outcomes is unknown. We evaluated whether vitamin E treatment improves clinical outcomes of NASH patients with bridging fibrosis or cirrhosis.

Yukihiro Sanada, Shuji Hishikawa, Takumi Katano, Yuta Hirata, Naoya Yamada, Noriki Okada, Koichi Mizuta – 1 December 2018

Stefania Gioia, Silvia Nardelli, Oliviero Riggio – 1 December 2018

Tatyana Kushner, Norah A. Terrault – 30 November 2018

Tian‐Cheng Li, Huimin Bai, Sayaka Yoshizaki, Yasushi Ami, Yuriko Suzaki, Yen Hai Doan, Kazuaki Takahashi, Shunji Mishiro, Naokazu Takeda, Takaji Wakita – 30 November 2018 – Neither an animal model nor a cell culture system has been established for the genotype 5 hepatitis E virus (G5 HEV), and the pathogenicity, epidemiology, and replication mechanism of the virus remain unclear. In this study, we used a reverse genetics system to generate G5 HEV and examined the possibility of zoonotic infection.

Andreia Ribeiro, Maria‐Jose Igual‐Perez, Ermelinda Santos Silva, Etienne M. Sokal – 30 November 2018 – Nonalcoholic fatty liver disease (NAFLD) is an emerging entity, becoming the most prevalent pediatric chronic liver disease. Its broad spectrum of histological findings, comorbidities, and complications, including cirrhosis and liver failure, can occur in childhood, emphasizing the severity of pediatric NAFLD.

Runping Liu, Vishwadeep Ahluwalia, Jason D. Kang, Siddhartha S. Ghosh, Huiping Zhou, Yunzhou Li, Derrick Zhao, Emily Gurley, Xiaojiaoyang Li, Melanie B. White, Andrew Fagan, H. Robert Lippman, James B. Wade, Phillip B. Hylemon, Jasmohan S. Bajaj – 30 November 2018 – Patients with cirrhosis are growing older, which could have an impact on brain dysfunction beyond hepatic encephalopathy. Our aim was to study the effect of concomitant aging and cirrhosis on brain inflammation and degeneration using human and animal experiments.

Tatyana Kushner, Norah A. Terrault – 30 November 2018